Top Markets
Coin of the day
Radiopharm Theranostics Limited Radiopharm Theranostics Limited

Radiopharm Theranostics Limited

RAD
Classifica tra le azioni #29689
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company,... Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
Prezzo delle azioni
$0.00846342
Capitalizzazione di mercato
$20.02M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-47.56%
Paese
AU
Scambia Radiopharm Theranostics Limited (RAD)

Categoria

Storico del prezzo dell'azione per Radiopharm Theranostics Limited (RAD)
Prezzo di chiusura più alto: $0.01 il 2026-08-01

Prezzo di chiusura più basso: $0.24 il 2021-11-01
Storico del prezzo dell'azione di Radiopharm Theranostics Limited dal 2021 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -22.80%
2025 -10.60%
2024 -63.52%
2023 -27.28%
2022 -71.97%
2021 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$527.89 35.09%
US
$996.61 51.72%
NL
$116.99 -19.63%
AU
$735.86 6.07%
CH
$257.75 14.92%
BE